VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Monday. The brokerage issued a sell rating on the stock.

Other equities analysts have also recently issued reports about the company. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Thursday, February 6th.

VolitionRx Stock Up 1.6 %

VNRX opened at $0.58 on Monday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.10. The business has a fifty day simple moving average of $0.61 and a 200-day simple moving average of $0.65. The firm has a market cap of $54.12 million, a P/E ratio of -1.62 and a beta of 1.20.

Insider Activity

In other news, Director Guy Archibald Innes acquired 174,764 shares of the company’s stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Cameron John Reynolds acquired 139,811 shares of VolitionRx stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently modified their holdings of VNRX. Ground Swell Capital LLC raised its stake in VolitionRx by 78.8% in the third quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock valued at $28,000 after buying an additional 20,249 shares in the last quarter. Northern Trust Corp increased its holdings in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of VolitionRx during the 4th quarter worth about $29,000. Millennium Management LLC purchased a new stake in VolitionRx during the fourth quarter worth approximately $36,000. Finally, Geode Capital Management LLC boosted its holdings in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.